David Y. Liu - 15 Feb 2022 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Scientific Officer
Signature
/s/ Donald A. Kalkofen, Attorney-in-Fact for David Y. Liu
Issuer symbol
PTGX
Transactions as of
15 Feb 2022
Net transactions value
$0
Form type
4
Filing time
17 Feb 2022, 18:25:38 UTC
Previous filing
19 Aug 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Award $0 +10,000 +17% $0.000000 68,657 15 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Award $0 -60,000 -50% $0.000000 60,000 15 Feb 2022 Common Stock 60,000 $28.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025.
F2 Includes an aggregate of 403 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2021.
F3 The stock option vests in 48 equal monthly installments following the date of grant.